Showing results (51-60 of 209) with videos related to
Sort By:
Pageof 21
Alimentary Pharmacology & Therapeutics|August 5, 2003
Review article: mild to moderate Crohn's disease--defining the basis for a new treatment algorithmW J Sandborn, B G FeaganMayo Clinic Proceedings|January 1, 1996
Methotrexate for inflammatory bowel disease: pharmacology and preliminary resultsL J Egan, W J SandbornMayo Clinic Proceedings|October 1, 1992
Cyclosporine treatment of inflammatory bowel diseaseW J Sandborn, W J TremaineDigestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|August 28, 2007
The natural history of perianal Crohn's diseaseS B Ingle, E V LoftusGut|October 16, 2001
Leucopenia resulting from a drug interaction between azathioprine or 6-mercaptopurine and mesalamine, sulphasalazine, or balsalazideP W Lowry, C L Franklin, A L Weaver, et al.Alimentary Pharmacology & Therapeutics|May 15, 2004
Comparative pharmacokinetics of equimolar doses of 5-aminosalicylate administered as oral mesalamine (Asacol) and balsalazide: a randomized, single-dose, crossover study in healthy volunteersW J Sandborn, S B Hanauer, A BuchAlimentary Pharmacology & Therapeutics|January 16, 2007
Review article: biological activity markers in inflammatory bowel diseaseD Desai, W A Faubion, W J SandbornInflammatory Bowel Diseases|February 24, 1999
Medical therapy for induction and maintenance of remission in pouchitis: a systematic reviewW J Sandborn, R McLeod, D P JewellAlimentary Pharmacology & Therapeutics|January 16, 2004
Systematic review: short-term adverse effects of 5-aminosalicylic acid agents in the treatment of ulcerative colitisE V Loftus, S V Kane, D BjorkmanClinical Pharmacology and Therapeutics|July 26, 2012
Evolving molecular targets in the treatment of nonmalignant gastrointestinal diseasesD A Katzka, E V Loftus, M CamilleriPageof 21